Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: Specific changes in Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 11, Issue 4, 2000, Pages 181-186

  Eckert, G P ^a,c   Cairns, N J ^b   Maras, A ^c   Gattaz, W F ^d   Muller W E ^a,c  

^a GOETHE UNIVERSITY   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alzheimer's disease; Apolipoprotein E; Cholesterol; Human brain; Membrane alterations; Neurotoxicity; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN; CHOLESTEROL;

ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MEMBRANE FLUIDITY; NEUROTOXICITY; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0034125199     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000017234     Document Type: Article

References (45)

1. Yankner BA, Duffy LK, Kirschner DA: Neurotrophic and neurotoxic effects of amyloid beta protein: Reversal by tachykinin neuropeptides. Science 1990;250:279-282.
2. Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW: Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur J Pharmacol 1991;207:367-368.
3. Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE: Evidence for excito-protective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 1993;10:243-254.
4. Hartmann H, Eckert A, Müller WE: Beta-amyloid protein amplifies calcium signalling in central neurons from the adult mouse. Biochem Biophys Res Commun 1993;194:1216-1220.
5. Carette B, Poulain P, Delacourte A: Electrophysiological effects of 25-35 amyloid-beta-protein on guinea-pig lateral septal neurons. Neurosci Lett 1993;151:111-114.
6. Kelly JF, Furukawa K, Barger SW, Rengen MR, Mark RJ, Blanc EM, Roth GS, Mattson MP: Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc Natl Acad Sci USA 1996;93:6753-6758.
7. Keller JN, Pang Z, Geddes JW, Begley JG, Germeyer A, Wacg G, Mattson MP: Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: Role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem 1997;69:273-284.
8. Mark RJ, Pang Z, Geddes JW, Uchida K, Mattson MP: Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: Involvement of membrane lipid peroxidation. J Neurosci 1997;17:1046-1054.
9. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA: A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer's disease. Proc Natl Acad Sci USA 1994;91:3270-3274.
10. 1-43. Amyloid 1998;5:10-15.
11. Avdulov NA, Chochina SV, Igbavboa U, O'Harc EO, Schroeder F, Cleary JP, Wood WG: Amyloid beta-peptides increase annular and bulk fluidity and induce lipid peroxidation in brain synaptic plasma membranes. J Neurochem 1997;68:2086-2091.
12. Chauhan A, Chauhan VPS, Brockerhoff H, Wisniewski HM: Effect of amyloid beta-protein on membrane properties; in Corain A, Iqbal K, Nicolini M, Winblad B, Wisniewski H, Zatta P (eds): Alzheimer's Disease: Advances in Clinical and Basic Research. New York, Wiley, 1993, pp 431-439.
13. Müller WE, Hartmann H, Eckert GP, Eckert A, Eisert S: Cholesterol affects neuronal calcium signalling. A possible link between apolipoprotein polymorphism, beta-amyloid neurotoxicity, and neurodegeneration in Alzheimer's disease. Nutr Metab Card Dis 1997;7:210-216.
14. Müller WE, Koch S, Eckert A, Hartmann H, Scheuer K.: Beta-amyloid peptide decreases membrane fluidity. Brain Res 1995;674:133-136.
15. Matsuzaki K, Horikiri C: Interactions of amyloid β-peptide (1-40) with ganglioside-containing membranes. Biochemistry 1999;38:4137-4142.
16. Mecocci P, Cherubini A, Beal MF, Cecchetti R, Chionne F, Polidori MC, Romano G, Senin U: Altered mitochondrial membrane fluidity in AD brain. Neurosci Lett 1996;207:129-132.
17. Scheuer K, Maras A, Gattaz WF, Cairns N, Förstl H, Müller WE: Cortical NMDA receptor properties and membrane fluidity are altered in Alzheimer's disease. Dementia 1996;7:210-214.
18. Mason RP, Shoemaker WJ, Shajenko L, Chambers TE, Herbette LG: Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol Aging 1992;13:413-419.
19. Hajimohammadreza I, Brammer M: Brain membrane fluidity and lipid peroxidation in Alzheimer's disease. Neurosci Lett 1990;112: 333-337.
20. Zubenko GS: Hippocampal membrane alteration in Alzheimer's disease. Brain Res 1986; 385:115-121.
21. Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR: Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 1998;23:81-88.
22. Farooqui AA, Rapoport SI, Horrocks LA: Membrane phospholipid alterations in Alzheimer's disease: Deficiency of ethanolamine plasmalogens. Neurochem Res 1997;22:523-527.
23. Wells K, Farooqui AA, Liss L, Horroeks LA: Neural membrane phospholipids in Alzheimer's disease. Neurochem Res 1995;20:1329-1333.
24. Mason RP, Trumbore MW, Pettegrew JW: Membrane interactions of a phosphomonoester elevated early in Alzheimer's disease. Neurobiol Aging 1995;16:531-539.
25. Wood WG, Schroeder F, Avdulov NA, Chochina SV, Igbavboa U: Recent advances in brain cholesterol dynamics: Transport, domains, and Alzheimer's disease. Lipids 1999;34:225-234.
26. Zhou Y, Richardson JS: Cholesterol protects PC 12 cells from beta-amyloid induced calcium disordering and cytotoxicity. Neuroreport 1996;7:2487-2490.
27. Tierney MC, Fisher RH, Lewis AJ, Zorzitto ML, Snow WG, Reid DW. Nieuwstraten P: The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: A clinicopathologic study of 57 cases. Neurology 1988;38:359-364.
28. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JD, von Belle G, Bert L: The consortium to establish a registry for Alzheimer's disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
30. Lentz BR: Membrane fluidity from anisotropy measurements; in Loew LM (ed): Spectroscopic Membrane Probes. Boca Raton, CRC Press, 1988, pp 13-42.
31. LeVine H 3d: Thioflavin T interaction with synthetic Alzheimer's disease beta-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci 1993;2:404-410.
32. 2+-ATPase activity, interdigitation, and increases fluidity of brain synaptic plasma membranes. Brain Res 1995;683:36-42.
33. Mulders F, van Langen H, Van Ginkel G, Levine YK: The static dynamic behaviour of fluorescent probe molecules in lipid bilayers. Biochim Biophys Acta 1986;859:209-218.
34. Mecocci P, Beal MF, Cecchetti R, Polidori MC, Cherubini A, Chionne F, Avellini L, Romano G, Senin U: Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Mol Chem Neuropathol 1997;31:53-64.
35. Hudson B, Cavalier S: Studies on membrane dynamics and lipid-protein interactions with parinaric acid; in Loew LM (ed): Spectroscopic Membrane Probes. Boca Raton, CRC Press, 1988, pp 43-62.
36. Svennerholm L, Gottfries CG: Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J Neurochem 1994; 62:1039-1047.
37. Burdick D, Kosmoski J, Knauer MF, Glabe CG: Preferential adsorption, internalization and resistance to degradation of the major isoform of the Alzheimer's amyloid peptide. A beta 1-42, in differentiated PC12 cells. Brain Res 1997;746:275-284.
38. Good TA, Murphy RM: Aggregation state-dependent binding of beta-amyloid peptide to protein and lipid components of rat cortical homogenates. Biochem Biophys Res Commun 1995;207:209-215.
39. Mason RP, Shoemaker WJ, Shajenko L, Herbette LG: X-ray diffraction analysis of brain lipid membrane structure in Alzheimer's disease and beta-amyloid peptide interactions. Ann N Y Acad Sci 1993;695:54-58.
40. Mann DM, Iwatsubo T, Ihara Y, Cairns NJ, Lantos PL, Bogdanovic N, Lannfelt L, Winblad B, Maat-Schieman ML, Rossor MN: Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am J Pathol 1996;148:1257-1266.
41. Roses AD, Strittmatter WJ, Pericak-Vance MA, Corder EH, Saunders AM, Schmechel DE: Clinical application of apolipoprotein E genotyping to Alzheimer's disease. Lancet 1994;343:1564-1565.
42. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, et al: Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc Natl Acad Sci USA 1995;92:12260-12264.
43. Klunk WE, Panchalingam K, McClure RJ, Stanley JA, Pettegrew JW: Metabolic alterations in postmortem Alzheimer's disease brain are exaggerated by Apo-E4. Neurobiol Aging 1999;19:511-515.
44. Hartmann H, Eckert A, Müller WE: Apolipoprotein E and cholesterol affect neuronal calcium signalling: The possible relationship to beta-amyloid neurotoxicity. Biochem Biophys Res Commun 1994;200:1185-1192.
45. Howland DS, Trusko SP, Savage MJ, Reaume AG, Lang DM, Hirsch JD, Maeda N, Siman R, Greenberg BD, Scott RW, Flood DG: Modulation of secreted β-amyloid precursor protein and amyloid β-peptide in brain by cholesterol. J Biol Chem 1998;273:16576-16582.